All In Biotech

Free tool

FAERS Monitor: Bss

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020742 or its brand name (Bss, Calcium Chloride, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, Sodium Citrate). Reports on generic versions are filed under their own applications.

Reports

1,293

Serious

1,129

87% of reports

Hospitalization

117

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • toxic anterior segment syndrome509
  • endophthalmitis313
  • hypopyon109
  • eye inflammation100
  • corneal oedema99
  • off label use86
  • post procedural complication79
  • vision blurred74
  • eye pain70
  • anterior chamber cell63
  • visual acuity reduced55
  • visual impairment54
  • anterior chamber fibrin47
  • ocular hyperaemia45
  • vitritis44

Reports by year received

View as table
YearReports
200422
20053
200679
200736
200846
200936
201024
201137
2012104
201383
201469
201588
2016132
2017116
201866
201936
202017
202158
202289
202335
202436
202551
202630

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,866 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
toxic anterior segment syndromeSignal50914239.912811.33,858,613
anterior chamber fibrinSignal479332.56547.5272,858
hypopyonSignal1092468.42033.2231,316
anterior chamber cellSignal631575.71223.788,968
endophthalmitisSignal313895.3810.2264,272
corneal oedemaSignal99751.8619.370,249
vitritisSignal44396.0295.116,544
eye inflammationSignal100172.3142.616,689
post procedural complicationSignal7967.254.25,068
visual acuity reducedSignal5527.020.81,350
eye painSignal7020.216.11,261
ocular hyperaemiaSignal4515.411.6594
vision blurredSignal748.87.0505
visual impairmentSignal547.15.5278
off label use861.61.319

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.